These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11403595)

  • 1. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein--protein interaction.
    Last-Barney K; Davidson W; Cardozo M; Frye LL; Grygon CA; Hopkins JL; Jeanfavre DD; Pav S; Qian C; Stevenson JM; Tong L; Zindell R; Kelly TA
    J Am Chem Soc; 2001 Jun; 123(24):5643-50. PubMed ID: 11403595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the allosteric inhibition of a protein-protein interaction by mass spectrometry.
    Davidson W; Hopkins JL; Jeanfavre DD; Barney KL; Kelly TA; Grygon CA
    J Am Soc Mass Spectrom; 2003 Jan; 14(1):8-13. PubMed ID: 12504329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold.
    Potin D; Launay M; Nicolai E; Fabreguette M; Malabre P; Caussade F; Besse D; Skala S; Stetsko DK; Todderud G; Beno BR; Cheney DL; Chang CJ; Sheriff S; Hollenbaugh DL; Barrish JC; Iwanowicz EJ; Suchard SJ; Dhar TG
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1161-4. PubMed ID: 15686933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alphal subunit of lymphocyte function-associated antigen-1.
    Keating SM; Clark KR; Stefanich LD; Arellano F; Edwards CP; Bodary SC; Spencer SA; Gadek TR; Marsters JC; Beresini MH
    Protein Sci; 2006 Feb; 15(2):290-303. PubMed ID: 16384997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the binding site in intercellular adhesion molecule 1 for its receptor, leukocyte function-associated antigen 1.
    Fisher KL; Lu J; Riddle L; Kim KJ; Presta LG; Bodary SC
    Mol Biol Cell; 1997 Mar; 8(3):501-15. PubMed ID: 9188101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic control of allosteric antagonism of leukocyte function antigen-1 and intercellular adhesion molecule-1 interaction.
    Nam K; Maiorov V; Feuston B; Kearsley S
    Proteins; 2006 Aug; 64(2):376-84. PubMed ID: 16705652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding.
    Huth JR; Olejniczak ET; Mendoza R; Liang H; Harris EA; Lupher ML; Wilson AE; Fesik SW; Staunton DE
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5231-6. PubMed ID: 10805782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The determination and correlation of molecular and cellular equilibrium Kd and kinetic k(off) values for small molecule allosteric antagonists of LFA-1.
    Caviness GO; Labadia ME; Giblin PA; Woska JR; Last-Barney K; Jeanfavre DD; Morelock MM
    Biochem Pharmacol; 2007 Jun; 74(1):98-106. PubMed ID: 17482579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).
    Watterson SH; Xiao Z; Dodd DS; Tortolani DR; Vaccaro W; Potin D; Launay M; Stetsko DK; Skala S; Davis PM; Lee D; Yang X; McIntyre KW; Balimane P; Patel K; Yang Z; Marathe P; Kadiyala P; Tebben AJ; Sheriff S; Chang CY; Ziemba T; Zhang H; Chen BC; DelMonte AJ; Aranibar N; McKinnon M; Barrish JC; Suchard SJ; Murali Dhar TG
    J Med Chem; 2010 May; 53(9):3814-30. PubMed ID: 20405922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry.
    Crump MP; Ceska TA; Spyracopoulos L; Henry A; Archibald SC; Alexander R; Taylor RJ; Findlow SC; O'Connell J; Robinson MK; Shock A
    Biochemistry; 2004 Mar; 43(9):2394-404. PubMed ID: 14992576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The second domain of intercellular adhesion molecule-1 (ICAM-1) maintains the structural integrity of the leucocyte function-associated antigen-1 (LFA-1) ligand-binding site in the first domain.
    Stanley P; McDowall A; Bates PA; Brashaw J; Hogg N
    Biochem J; 2000 Oct; 351(Pt 1):79-86. PubMed ID: 10998349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties.
    Liu G; Huth JR; Olejniczak ET; Mendoza R; DeVries P; Leitza S; Reilly EB; Okasinski GF; Fesik SW; von Geldern TW
    J Med Chem; 2001 Apr; 44(8):1202-10. PubMed ID: 11312920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular activation of leukocyte function-associated antigen-1 and its affinity are regulated at the I domain allosteric site.
    Lupher ML; Harris EA; Beals CR; Sui LM; Liddington RC; Staunton DE
    J Immunol; 2001 Aug; 167(3):1431-9. PubMed ID: 11466362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion.
    Anderson ME; Tejo BA; Yakovleva T; Siahaan TJ
    Chem Biol Drug Des; 2006 Jul; 68(1):20-8. PubMed ID: 16923022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICAM-1 peptide inhibitors of T-cell adhesion bind to the allosteric site of LFA-1. An NMR characterization.
    Zimmerman T; Oyarzabal J; Sebastián ES; Majumdar S; Tejo BA; Siahaan TJ; Blanco FJ
    Chem Biol Drug Des; 2007 Oct; 70(4):347-53. PubMed ID: 17868072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1.
    Lu C; Shimaoka M; Salas A; Springer TA
    J Immunol; 2004 Sep; 173(6):3972-8. PubMed ID: 15356146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance.
    Weitz-Schmidt G
    Endothelium; 2003; 10(1):43-7. PubMed ID: 12699076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain.
    Kallen J; Welzenbach K; Ramage P; Geyl D; Kriwacki R; Legge G; Cottens S; Weitz-Schmidt G; Hommel U
    J Mol Biol; 1999 Sep; 292(1):1-9. PubMed ID: 10493852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule.
    Gadek TR; Burdick DJ; McDowell RS; Stanley MS; Marsters JC; Paris KJ; Oare DA; Reynolds ME; Ladner C; Zioncheck KA; Lee WP; Gribling P; Dennis MS; Skelton NJ; Tumas DB; Clark KR; Keating SM; Beresini MH; Tilley JW; Presta LG; Bodary SC
    Science; 2002 Feb; 295(5557):1086-9. PubMed ID: 11834839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The functional interaction of the beta 2 integrin lymphocyte function-associated antigen-1 with junctional adhesion molecule-A is mediated by the I domain.
    Fraemohs L; Koenen RR; Ostermann G; Heinemann B; Weber C
    J Immunol; 2004 Nov; 173(10):6259-64. PubMed ID: 15528364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.